ARCA biopharma (ABIO) Receiving Somewhat Favorable News Coverage, Report Finds
News stories about ARCA biopharma (NASDAQ:ABIO) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ARCA biopharma earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.4833348163702 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
ARCA biopharma (NASDAQ ABIO) remained flat at $$1.20 during trading on Tuesday. 46,176 shares of the company traded hands, compared to its average volume of 71,542. ARCA biopharma has a twelve month low of $1.05 and a twelve month high of $3.00.
ARCA biopharma (NASDAQ:ABIO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) EPS for the quarter.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/07/arca-biopharma-abio-receiving-somewhat-favorable-news-coverage-report-finds.html.
About ARCA biopharma
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Stock Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related stocks with our FREE daily email newsletter.